Company intelligence / Profile preview

MEDRx

Higashikagawa, Kagawa, Japanmedrx-diagnostics.com ↗

Ownership: Public · 4586
Development stage: Other

Overview

MEDRx specializes in innovative drug formulation and transdermal drug delivery technologies, including proprietary platforms like ILTS® and NCTS®. The company aims to improve patient compliance and expand treatment options by enabling drugs with poor oral bioavailability or solubility to be delivered transdermally. Some products have advanced into clinical development, but detailed clinical results are not publicly summarized in available sources.

Therapeutic areas: Other
Modalities: Small moleculeBiologicTransdermal drug delivery system (platform)Microneedle-based therapy (platform)
Industry: Biotech

Drug pipeline

2 assets

MRX-6LDT

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships specifically named in available sources.

Beyond the preview

Go deeper on MEDRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDRx.

Explore the full profile